Ayala Pharmaceuticals Stock Net Asset
| ADXSDelisted Stock | USD 1.38 0.34 32.69% |
Ayala Pharmaceuticals fundamentals help investors to digest information that contributes to Ayala Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Ayala OTC Stock. The fundamental analysis module provides a way to measure Ayala Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ayala Pharmaceuticals otc stock.
Ayala |
Ayala Pharmaceuticals OTC Stock Net Asset Analysis
Ayala Pharmaceuticals' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
CompetitionBased on the recorded statements, Ayala Pharmaceuticals has a Net Asset of 0.0. This indicator is about the same for the Healthcare average (which is currently at 0.0) sector and about the same as Biotechnology (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Ayala Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ayala Pharmaceuticals' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Ayala Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Ayala Pharmaceuticals by comparing valuation metrics of similar companies.Ayala Pharmaceuticals is currently under evaluation in net asset category among its peers.
Ayala Fundamentals
| Return On Equity | -41.98 | ||||
| Return On Asset | -24.13 | ||||
| Current Valuation | (25.1 M) | ||||
| Shares Outstanding | 145.64 M | ||||
| Shares Owned By Insiders | 0.01 % | ||||
| Shares Owned By Institutions | 0.10 % | ||||
| Number Of Shares Shorted | 39.89 K | ||||
| Price To Earning | (1.62) X | ||||
| Price To Book | 5.25 X | ||||
| Price To Sales | 990.34 X | ||||
| Revenue | 250 K | ||||
| Gross Profit | 3.24 M | ||||
| EBITDA | (15.31 M) | ||||
| Net Income | (16.24 M) | ||||
| Cash And Equivalents | 28.15 M | ||||
| Cash Per Share | 15.50 X | ||||
| Total Debt | 19 K | ||||
| Current Ratio | 15.64 X | ||||
| Book Value Per Share | 0.32 X | ||||
| Cash Flow From Operations | (16.04 M) | ||||
| Short Ratio | 0.95 X | ||||
| Earnings Per Share | (0.33) X | ||||
| Number Of Employees | 14 | ||||
| Beta | 2.28 | ||||
| Market Capitalization | 247.58 M | ||||
| Total Asset | 169.04 M | ||||
| Retained Earnings | (354.94 M) | ||||
| Working Capital | 132.17 M | ||||
| Current Asset | 159.88 M | ||||
| Current Liabilities | 27.71 M |
About Ayala Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ayala Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ayala Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ayala Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Other Consideration for investing in Ayala OTC Stock
If you are still planning to invest in Ayala Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ayala Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |